Neuropsychiatric Drugs Market
完整報告名稱與涵蓋範圍
Neuropsychiatric Drugs Market Size, Share & Trends Analysis Report By Drug Type (Typical Antipsychotics and Atypical Antipsychotics), By Indication, By Route Of Administration, Region And Segment Forecasts, 2025-2034.
報告摘要
Industry analysis indicates the Neuropsychiatric Drugs Market globally will advance at a 5.0% CAGR during 2025–2034.
At its core, Neuropsychiatric Drugs pertains to psychological disorder occur owing to a functional disturbance in the cerebral system. Stakeholders across the healthcare landscape are growingly turning to these solutions to meet contemporary demands.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the growing emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neuropsychiatric Drugs Market Snapshot
Chapter 4. Global Neuropsychiatric Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 2: By Drug Types Estimates & Trend Analysis
5.1. By Drug Types & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Types:
5.2.1. Typical Antipsychotics
5.2.1.1. Prochlorperazine
5.2.1.2. Haloperidol
5.2.1.3. Others
5.2.2. Atypical Antipsychotics
5.2.2.1. Aripiprazole
5.2.2.2. Asenapine
5.2.2.3. Cariprazine
5.2.2.4. Clozapine
5.2.2.5. Lurasidone
5.2.2.6. Olanzapine
5.2.2.7. Risperidone
5.2.2.8. Others
Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Schizophrenia
6.2.2. Bipolar Disorder
6.2.3. Psychotic Depression
6.2.4. Other Indications
Chapter 7. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
7.1. By Route of Administration & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
7.2.1. Oral
7.2.2. Parenteral
Chapter 8. Neuropsychiatric Drugs Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts By Drug Types, 2021-2034
8.1.2. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
8.1.3. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
8.1.4. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, 2021-2034
8.2.2. Europe Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, 2021-2034
8.2.3. Europe Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
8.2.4. Europe Neuropsychiatric Drugs Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, 2021-2034
8.3.2. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, 2021-2034
8.3.3. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
8.3.4. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, (US$ Million)
8.4.2. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, (US$ Million)
8.4.3. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
8.4.4. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, (US$ Million)
8.5.2. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, (US$ Million)
8.5.3. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
8.5.4. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) by country, (US$ Million) 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novartis
9.2.2. Pfizer
9.2.3. Otsuka
9.2.4. Allergan
9.2.5. Eli Lilly
9.2.6. Sunovion
9.2.7. AstraZeneca
9.2.8. Actavis Laboratories
9.2.9. Johnson & Johnson
9.2.10. Bristol Myers Squibb
9.2.11. Sage Therapeutics
9.2.12. BlackThorn Therapeutics
9.2.13. BioXcel Therapeutics
9.2.14. Lundbck A/S
9.2.15. Takeda
9.2.16. Cerevel Therapeutics, LLC
9.2.17. INmune Bio
9.2.18. Perception Neuroscience
9.2.19. Psilera Bioscience
9.2.20. Eleusis Holdings Ltd
9.2.21. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們